The Effect of Treatment with the Complement C5a Receptor Inhibitor Avacopan on Health-Related Quality of Life in ANCA-Associated Vasculitis
10:00am - 10:00am EDT - March 20, 2022
10:00am - 10:00am EDT - March 20, 2022
Author(s):
- Vibeke Strand, Division of Immunology and Rheumatology, Stanford University
- Pirow Bekker, ChemoCentryx, Inc.
- Huibin Yue, ChemoCentryx, Inc.
- David R. W. Jayne, Department of Medicine, University of Cambridge
- Peter A. Merkel, Division of Rheumatology, University of Pennsylvania
| Display Label | Action |
|---|---|
| RNL22P7 - The Effect of Treatment with the Complement C5a Receptor Inhibitor Avacopan on Health-Related Quality of Life in ANCA-Associated Vasculitis | Download MP3 |